Full title: Lifecourse Genome-Wide Association Study Meta-Analysis Refines the Critical Life Stages for Adiposity's Influence on Breast Cancer Risk

Short title: Lifecourse Influence of Adiposity on Breast Cancer

Authors: Grace M. Power[1,2,3], Laxmi Bhatta[4,5,6], Amanda M. Hughes[1,2,7], Carolina Medina-Gomez[8], Anne Richmond[9], Genevieve Leyden[1,2], Bethan Lloyd-Lewis[1,10], Eleanor Sanderson[1,2], Rebecca Richmond[1,2], Elizabeth C. Corfield[1,2,7,11], Daniel McCartney[9], Caroline Hayward[9,12], Irene Fontes Marques[13,14], Fernando Rivadeneira[8], Bjørn Olav Åsvold[4,15,16], Gibran Hemani[1,2], Janine F. Felix[13,14], Ben Brumpton[4,15,17], Alexandra Havdahl[7,11,18], George Davey Smith[1,2,19]

Affiliations

1. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
2. Population Health Sciences, Bristol Medical School, University of Bristol, UK.
3. Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
4. HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Trondheim, Norway.
5. Division of Mental Health Care, St Olavs Hospital, Trondheim, Norway.
6. Department of Clinical and Molecular Medicine, NTNU Norwegian University of Science and Technology, Trondheim, Norway.
7. PsychGen Centre for Genetic Epidemiology and Mental Health, Norwegian Institute of Public Health, Oslo Norway.
8. Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, CA 3000, The Netherlands.
9. Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
10. School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
11. Research Department, Lovisenberg Diaconal Hospital, Oslo, Norway
12. MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.
13. Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
14. Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
15. HUNT Research Centre, Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Levanger, Norway.
16. Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
17. Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
18. PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway
19. NIHR Bristol Biomedical Research Centre Bristol, University Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK.

Abstract

Previous evidence suggests that higher prepubertal adiposity protects against breast cancer risk. Whether this protection extends into early adulthood remains uncertain. We conducted genome-wide association studies on body mass index (BMI) in nulliparous women from menarche to <40 years across five cohorts, with additional analyses in three sub-intervals of this life stage. Results were meta-analysed, and two-sample univariable and multivariable Mendelian randomisation was applied within a lifecourse framework to assess the effect of BMI on breast cancer risk. Between menarche and <40 years, we observed heterogeneity in genetic effects. Genome-wide correlations further suggest BMI during this early adult period may be partly influenced by distinct genetic factors compared with adiposity at other life stages. Higher genetically proxied BMI between menarche and 40 years reduced breast cancer risk. This protective effect attenuated after adjusting for prepubertal adiposity. These findings refine our understanding of adiposity's role in breast cancer and highlight earlier life stages as critical windows for risk modulation.

Teaser

Improving knowledge of adiposity's genetic architecture across the lifecourse refines insights into its role in breast cancer

Introduction

Breast cancer is the most commonly diagnosed cancer in women worldwide, with over 2.3 million new cases and 685,000 deaths reported in 2020 (*1*). Nearly 99% of women diagnosed at the earliest stage survive for 5 years or more, compared to approximately 32% of those diagnosed at the most advanced stage (*2*). This underscores the importance of improving early detection and highlights the need to identify preventative strategies as key public health objectives.

Breast tissue is particularly vulnerable to exposures between menarche and first full-term pregnancy – a critical window of susceptibility (*3*). After menarche, the breast epithelium undergoes rapid cellular proliferation leading to an increased risk of acquiring mutation during puberty and until the terminal ductal differentiation that accompanies the first full-term pregnancy (*4, 5*). Evidence suggests that certain exposures such as physical activity (*3*), may alleviate the risk of breast cancer, while others, such as alcohol consumption (*6*), a known breast carcinogen (*7*), may exacerbate it, by acting during this period of tumorigenic susceptibility. By investigating whether known factors influencing breast cancer risk also exert effects during this timeframe, we may be better able to identify strategies for more effective breast cancer risk detection and potential avenues for prevention. Focusing on this period may additionally enable a more precise assessment by minimising the confounding effects of physiological changes associated with first birth.

Mendelian randomization (MR) is a technique that exploits the quasi-random distribution of genetic variants from parents to offspring, independent of the influence from other traits. Under specific assumptions, MR aims to estimate causal effects by reducing susceptibility to confounding factors, including confounding by undiagnosed existing disease and disease processes (reverse causation) (*8, 9*). Recent developments in lifecourse MR methodology include multivariable MR (MVMR) (*10-12*). This approach enables the direct estimation of the effects of an exposure measured at a specific life stage, controlling for the same exposure measured at another life stage, on later life outcomes. Previous MVMR analyses suggest that a larger prepubertal body size, employed as a proxy for BMI, is protective against breast cancer (*13-16*). This protective effect persists even after controlling for later life adult body size, which has a negligible effect on breast cancer risk when prepubertal body size is controlled for. These findings align with conventional analyses (*17-23*) and have been further supported through a proxy-genotype MR approach, where offspring genotype proxies parental genotype to assess associations with parental disease risk (*24*). It has been proposed that such findings may be influenced by selection bias, as both childhood adiposity and breast cancer status could affect the likelihood of surviving to or participating in large-scale cohort studies (*25*). However, simulations examining the relationship between childhood body size and subsequent breast cancer risk indicate that, although bias can arise – particularly under interaction-driven

selection (*26*) – the magnitude remains insufficient to account for the protective effects observed in MR analyses (*27*).

Although a larger body size in childhood has been shown to reduce breast cancer risk, it also leads to earlier menarche, a known risk factor for breast cancer (*13*). This dual effect suggests that the protective direct effect of prepubertal body size on breast cancer could be larger than its total observed effect, as it may be partially attenuated by an increased risk mediated through earlier menarche. This interplay highlights two potentially independent pathways that may interact in complex ways. Despite convincing evidence for the protective effects of prepubertal body size on breast cancer risk, the time period at which this protective effect diminishes is yet to be determined using causal inference methods.

We aimed to estimate the effect of higher BMI between menarche and first full-term pregnancy – or throughout early adulthood (<40 years) in individuals who remain nulliparous – on breast cancer risk later in life. This previously understudied period represents a critical window of susceptibility to exposures influencing breast cancer risk. We first conducted genome-wide association studies (GWAS) of BMI in nulliparous women from five population-based cohorts across the full period from menarche to <40 years, and then stratified the analyses into three groups: menarche to <20 years, 20 to <30 years, and 30 to <40 years. This approach allowed us to assess the consistency of genetic variant effects on BMI across early adulthood and to apply these profiles in downstream lifecourse MR analyses. We then assessed these effects on overall breast cancer and different subtypes, including ER status (ER+/ER-) and five molecular subtypes: Luminal A-like, Luminal B-like (HER2-positive), Luminal B (HER2-negative-like), HER2-enriched, and triple-negative breast cancer using data from the Breast Cancer Association Consortium (BCAC) (*28, 29*). While we were not able to assess effects by menopausal status directly, we examined subtype-specific effects as a means of providing preliminary insights given that certain subtypes are more commonly diagnosed before or after menopause.

Results

Measurements of body mass index (BMI) between menarche and age <40 years were available for 56,863 nulliparous women across five cohorts: the Avon Longitudinal Study of Parents and Children (ALSPAC), the Trøndelag Health Study (HUNT), the Norwegian Mother, Father and Child Cohort Study (MoBa), Generation R, and Generation Scotland. Corresponding phenotype sample sizes and cohort characteristics for age and BMI are presented in Table 1. Within the primary <40 year group, mean ages at measurement ranged from 23.9 years in ALSPAC to 29.4 years in Generation R, while mean BMI values varied between 22.8 kg/m² in ALSPAC and 24.5 kg/m² in Generation Scotland. To explore patterns across narrower age intervals within this broader period, we also conducted analyses stratified into three groups: menarche to <20 years, 20 to <30 years, and 30 to <40 years. Phenotypic sample sizes and summary measures of age and BMI for the full <40 group and each stratum are shown in Table 1.

146 Table 1. Descriptive statistics for nulliparous women between menarche and <40 years,
147 menarche and <20 years, 20 and <30 years and 30 and <40 years, across all cohorts.
148

			Age (years)		BMI (kg/m^2)	
	Cohort	N	Mean (SD)	Median (Min-Max)	Mean (SD)	Median (Min-Max)
ALL (MENARCHE TO <40 YEARS)	ALSPAC	5047	23.92 (6.01)	24.00 (14.00-39.00)	22.79 (3.86)	21.98 (12.50-51.16)
	HUNT	7683	24.40 (5.04)	23.7 (12.80-39.90)	23.40 (3.99)	22.50 (15.34-52.20)
	MoBa	38687	25.75 (6.68)	27.00 (14.00-39.00)	23.16 (4.01)	22.38 (8.11-46.07)
	Generation R	2396	29.44 (4.71)	30.13 (15.96-39.95)	23.07 (4.04)	22.09 (14.53 - 49.82)
	Generation Scotland	3059	26.29 (5.95)	26.00 (14.00-39.00)	24.52 (5.28)	23.24 (13.13-57.94)
MENARCHE TO <20 YEARS	ALSPAC	2047	17.78 (0.42)	17.75 (14.00-19.33)	22.79 (4.10)	21.92 (13.11-50.06)
	HUNT	1093	16.90 (2.01)	17.00 (12.80-19.90)	21.95 (3.07)	21.48 (15.34-46.87)
	MoBa	7834	14.74 (1.22)	14.00 (14.00-19.00)	20.91 (3.06)	20.45 (8.92-40.75)
	Generation R					
	Generation Scotland	430	18.15 (0.94)	18.00 (14.00-19.00)	22.88 (3.96)	22.05 (15.5-43.09)
20 TO <30 YEARS	ALSPAC	3520	24.91 (2.12)	24.00 (20.00-29.00)	23.61 (4.44)	22.52 (14.22-57.88)
	HUNT	5507	24.18 (2.69)	23.70 (20.00-29.90)	23.50 (3.99)	22.7 (15.60-52.20)
	MoBa	18578	25.86 (2.51)	26.00 (20.00-29.00)	23.66 (4.05)	22.78 (8.11-45.31)
	Generation R	1127	26.08 (2.86)	26.62 (20.01 - 29.99)	23.24 (4.47)	22.20 (14.53 - 49.82)
	Generation Scotland	1745	24.41 (2.81)	24.00 (20.00-29.00)	24.31 (5.03)	23.12 (13.13-54.95)
30 TO <40YEARS	ALSPAC	1054	32.65 (2.45)	32.00 (30.00-39.00)	22.72 (3.65)	21.97 (12.50-47.30)
	HUNT	1083	33.09 (2.60)	32.30 (30.00-39.90)	24.32 (4.45)	23.30 (17.00-48.50)
	MoBa	12275	32.61 (2.38)	32.00 (30.00-39.00)	23.84 (3.97)	22.99 (8.50-46.07)
	Generation R	1269	33.12 (2.25)	32.76 (30.00 - 39.95)	22.98 (3.67)	22.06 (16.90 - 43.34)
	Generation Scotland	884	33.98 (2.85)	34.00 (30.00-39.00)	25.72 (6.00)	24.05 (13.7-57.94)

149
150
151 *Lifestage-stratified genome-wide association studies (GWAS) and meta-analysis*
152
153 Genome-wide association analyses (GWAS) for BMI were conducted in up to 56,628
154 nulliparous women with measures between menarche and age <40 years, and results were
155 meta-analysed across cohorts. Stratified meta-analyses for the three life stages – menarche to
156 <20 years, 20 to <30 years, and 30 to <40 years – included 11,365, 30,272 and 16,565,
157 respectively (Figure 1). For cohorts with repeat measures within one life stage (e.g., menarche
158 to <40 years), we retained the time point with the largest sample size (e.g., for ALSPAC, only
159 BMI data from participants <20 years were included). Considering results across all GWAS time
160 windows (menarche to <20, 20 to <30, 30 to <40, and the combined menarche to <40), we
161 identified a total of 45 independent variants.

Number of female participants with genotype data and BMI measured while nulliparous, by age category [a]

Menarche to <20 years					20 to <30 years					30 to <40 years				
ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland	ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland	ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland
2,047	1,093	7,834	N/A	391	3,520	5,507	18,578	1,127	1,540	1,054	1,083	12,275	1,269	884

Number of female participants with genotype data and BMI measured while nulliparous between menarche and <40 years [b]

ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland
5,047	7,683	38,687	2,396	2,815

a. this includes cohorts with repeat measures in the same individual for each age group category, b. for cohorts with repeat measures, this takes one measure within the age group with the largest sample size (e.g., for ALSPAC it only includes offspring BMI data from menarche to <20 year olds).

Figure 1. Overview of study participants used for this analysis

165 Overall, 31, 3, 12, and 5 lead genetic variants were identified as associated with BMI in
166 nulliparous women between menarche to <40 years, menarche to <20 years, 20 to <30 years,
167 and 30 to <40 years prior to giving birth, respectively, based on conventional genome-wide
168 significance ($P<5\times10^{-8}$) and LD clumping within each life stage to identify conditionally
169 independent signals (Table S1). Because clumping was conducted independently for each time
170 window, some loci are likely represented by different lead SNPs across groups, reflecting
171 tagging of the same underlying association signal. Additionally, because the narrower age
172 windows are nested within the broader menarche to <40 group, many SNPs identified in the
173 subgroups, or SNPs in high LD with them, also appear in the full-period analysis.

174 In total, 45 unique SNPs were identified across all groups. Nine loci reached genome-wide
175 significance in every life-stage GWAS (menarche to <40 years, <20 years, 20 to <30 years, and
176 30 to <40 years). Additional overlap was observed between the combined menarche to <40
177 years analysis and the stratified groups, with 9 loci genome-wide significant in both the
178 combined and <20 years groups, 26 in both the combined and 20 to <30 years groups, and 13
179 in both the combined and 30 to <40 years groups. Although such overlap is expected given the
180 nested design, these findings indicate that, while some loci were detected only within certain
181 intervals, a core set of loci consistently associated with BMI across adolescence and early
182 adulthood.

183 To assess redundancy and overlap across stages, we applied LD clumping to the compilation of
184 all 45 SNPs retained after stage-specific clumping. This revealed that they correspond to 31
185 independent genomic regions, indicating that several loci are shared across groups despite
186 being tagged by different SNPs. The majority of these independent signals were identified
187 within the menarche to <40 group, which is expected given its larger sample size and broader
188 coverage. SNPs that remained in the final set of 31 independent regions are marked in Table
189 S1.

190 Cochran's Q statistic was used to evaluate heterogeneity in SNP-exposure associations across
191 the five cohort studies included in the primary analysis. To account for multiple testing across
192 the 31 SNPs, a Bonferroni correction was applied. After adjustment, none of the variants
193 showed evidence of heterogeneity ($Q_{bonf}<0.05$), suggesting consistent effect estimates across
194 studies. This reinforces their validity in downstream MR analyses, reducing concerns
195 that study-level differences may confound associations with the outcome. Full heterogeneity
196 results, including uncorrected P-values and Q statistics, are provided in Table S2.
197
198 We visualised the life stage-specific effect trajectories of these SNPs at each life stage
199 (menarche to <20 years, 20 to <30 years and 30 to <40 years), with point size inversely
200 proportional to the standard error of the effect estimate (Figure S1). This revealed two notable
201 patterns of heterogeneity: (i) SNP effects in the 20 to <30-year life stage differ markedly from
202 those in the menarche to <20-year and 30 to <40-year life stages, and (ii) some SNPs show a
203 reversal in effect after age 30. Among 45 independent variants, nine showed substantial

heterogeneity across the three life stages (Q_{het}<0.05) (Figure 2). Given that the proportion of individuals from each cohort is comparable between the 20 to <30-year and 30 to <40-year life stages, the shift in effect estimates observed in the 20 to <30-year group is unlikely to be driven by a single cohort. These distinct patterns underscore age-specific heterogeneity that would likely be overlooked by linear meta-regression, highlighting the complexity of SNP effects on BMI over time.



Figure 2. Plot illustrating the age-specific effect trajectories of individual SNPs with significant heterogeneity (QFDR < 0.05) on BMI across three defined life stages: menarche to <20 years, 20 to <30 years, and 30 to <40 years, in nulliparous women. Each plot represents a SNP exhibiting significant heterogeneity (QFDR < 0.05), illustrating its effect size (beta) across life stages. Error bars denote 95% confidence intervals.

Heritability, LD score regression and genetic correlation analysis

We quantified the proportion of variance of the four meta-analyses undertaken on BMI in nulliparous women at different ages of European ancestry that can be explained by our SNP sets using Linkage Disequilibrium (LD) Score regression (*30*). The GWAS summary statistic SNP-based heritability ranged from 0.11 (SE = 0.01) for BMI in nulliparous women between 30 and <40 year olds, to 0.23 (SE = 0.02) for BMI in nulliparous women between 20 to <30 year olds (Table 2). These results indicate that genetic factors play an important role in BMI, particularly

223 in the younger life stages. The number of GWAS hits aligns with expectations, closely tracking
224 with heritability (h^2) and sample size, suggesting consistent polygenicity across life stages.

225 Table 2. Summary of meta-analysed genome-wide association results by life stage categories.
226

	Age group category			
Metric	BMI in nulliparous women between menarche and <40 years	BMI in nulliparous women between menarche and <20 years	BMI in nulliparous women between 20 and <30 years	BMI in nulliparous women between 30 and <40 years
	Estimate (SE)	Estimate (SE)	Estimate (SE)	Estimate (SE)
Heritability (Observed Scale h^2)	0.19 (0.01)	0.21 (0.03)	0.23 (0.02)	0.11 (0.01)
Genomic Inflation Factor (Lambda GC)	1.27	1.07	1.17	1.09
LD Score Regression Intercept	1.01 (0.01)	1.01 (0.01)	1.00 (0.01)	1.01 (0.01)
Proportion of Inflation (Ratio)	0.03 (0.02)	0.13 (0.08)	0.01 (0.04)	0.07 (0.06)

227
228 The genetic correlations (r_G) observed between prepubertal body size (used as a proxy for BMI)
229 in females and BMI at different stages in nulliparous women from menarche to <40 years
230 reveal consistently strong associations, as expected when investigating a similar phenotype
231 (BMI and body size) across different life stages. The r_G of 0.76 (SE = 0.02, P = 2.13×10^{-223})
232 between prepubertal body size in females and BMI in nulliparous women <40 years indicates
233 a high degree of shared genetic influence. This trend was mirrored at more granular age
234 intervals, with r_G values of 0.88, 0.74, and 0.71 for BMI in nulliparous women from menarche
235 to <20, 20 to <30, and 30 to <40 years, respectively (Figure 3). These results suggest
236 prepubertal body size has a slightly stronger genetic correlation in younger life stages,
237 particularly for BMI measured before age 20. Similarly, body size (used as a proxy for BMI) in
238 later life adult women shows strong genetic overlap with BMI measured in nulliparous women
239 at various age periods, with rG values ranging from 0.68 (for BMI in nulliparous women from
240 menarche to <20 years) to 0.95 (for BMI in nulliparous women aged 30 to <40 years). The
241 consistently high rG values across all comparisons, particularly the near-perfect correlation
242 between body size measured in later life adult women and BMI in nulliparous women aged 30
243 to <40 (rG = 0.95, SE = 0.05), may reflect an enduring genetic influence of BMI from
244 adolescence into later reproductive years (Figure 3; Table S3). The genetic correlation is
245 unaffected by differences in measurement scale, as it reflects shared genetic architecture
246 rather than observed variance. One r_G estimate calculated using LDSC slightly exceeded 1,
247 which is a known feature of the method due to sampling variability and its unconstrained
248 estimation framework. This value is not represented in the figure but is included in Table S3,
249 where all r_G values are reported. While overlapping samples can contribute to inflation, LDSC
250 intercepts adjust for this, and such values are not necessarily indicative of bias or
251 methodological error.



Figure 3. Genetic correlation heatmap for body mass index (BMI) and body size (used as a proxy for BMI) across various life stages in females, spanning from prepuberty through menarche and first birth to later adulthood.

Lifecourse Mendelian randomization (MR) analysis

Univariable MR analyses indicated evidence that a one standard deviation (SD) increase in genetically predicted log-transformed BMI in nulliparous women between menarche and <40 years reduced the risk of overall breast cancer (IVW odds ratio (OR), 95% CI: 0.76, 0.67 to 0.86, $P=1.27\times10^{-5}$) (Figure 4; Table S4). Similar inverse effects were observed across most breast cancer subtypes, except for the HER2-enriched subtype, which showed little evidence of protection. In multivariable MR accounting for later life adult body size, higher genetically predicted BMI in this window continued to provide evidence of a reduced risk of overall breast cancer and most subtypes, with HER2-enriched disease remaining the exception. Adjustment for prepubertal body size led to a marked, though not complete, attenuation of these effects, consistent with part of the protection being shared with childhood adiposity. Some evidence of a protective effect was observed for Luminal B-like (HER2+) tumours (Figure 4; Table S4).

In the narrower life-stage periods obtained by partitioning the broader fertile-window measure, univariable MR analyses indicated evidence that higher genetically predicted BMI in

nulliparous women between menarche to <20, 20 to <30, and 30 to <40 years reduced the risk of overall breast cancer and most subtypes, although the strength and precision of effects varied by subtype and life-stage period. After accounting for later life adult body size, protective effects were largely retained, with most estimates still supporting a reduction in risk. In contrast, adjusting for prepubertal body size removed much of the apparent protection in these narrower periods. For triple-negative disease, effect estimates suggested modest residual protection in the 20 to <30 window after accounting for childhood body size. Weighted median estimates were consistent in direction and magnitude. MR-Egger analyses provided little evidence of horizontal pleiotropy for the combined menarche to <40 exposure; for the narrower life-stage windows, estimates were imprecise due to limited statistical power (Table S4). To further assess the validity of the inferred causal direction, we applied Steiger filtering, which tests whether the genetic instruments explain more variance in the exposure than in the outcome. Across all life stages, the proportion of variance explained (R^2) was consistently higher for BMI than for breast cancer, supporting the hypothesised direction of effect from BMI to breast cancer (Table S5).

Using Mendelian Randomization Robust Adjusted Profile Score (MR-RAPS) with an instrument selection threshold of $P < 1 \times 10^{-5}$, genetically predicted BMI between menarche and <40 years, as well as between 20 and <30 years, showed strong evidence of a protective effect on overall breast cancer risk. Weaker evidence was observed for BMI between 30 and <40 years, while very little evidence of an effect was found for BMI between menarche and <20 years (Table S6).

Multivariable MR results should be interpreted with caution since conditional F-statistic was <10 for each of the BMI exposures included in these models, indicating potential for weak instrument bias (Table S4).



Figure 4. Univariable and multivariable Mendelian randomization (MR) for BMI between menarche and first birth on breast cancer (overall and subtype samples). A. The total effects (univariable MR). B. The direct effect accounting for childhood body size, and C. The direct effect accounting for later life adulthood body size (multivariable MR (MVMR)). The plots present the odds ratio of breast cancer per standard deviation (SD) increase in natural log-transformed BMI. Error bars indicate 95% confidence intervals around the point estimate from inverse-variance weighted (IVW) MR and IVW-MVMR analyses.

Sensitivity analyses

To minimise pregnancy-related confounding, we restricted the BMI GWAS to nulliparous women, which enabled a clearer assessment of BMI's direct influence across life stages. However, this restriction may introduce selection (collider) bias (*31*) if genetically proxied parity is associated with BMI within the nulliparous sample, as parity was not conditioned on in the breast cancer outcome GWAS. Our analyses indicated very little evidence that genetically proxied parity associated with BMI in nulliparous women between menarche and <40 years, menarche and <20 years, and 20 and <30 years. There was some evidence that genetically proxied parity associated with lower BMI in nulliparous women between 30 and <40 years (Table S7). There was very little evidence of effect in the reverse direction (BMI-associated variants on parity). These results suggest collider bias due to selecting nulliparous women is likely to be of little concern within this study.

After adjusting for age at menarche, the estimated effect of BMI in nulliparous women between menarche and <40 years on overall breast cancer remains largely consistent with the UVMR analyses (Table S8). Age at menarche itself showed little direct effect on overall breast cancer or most subtypes once BMI was accounted for.

Discussion

In this study, we undertook GWAS and MR analyses within a lifecourse framework to (i) assess the consistency of the genetic effects of BMI across different life stages, and (ii) investigate the effects of genetically proxied BMI in nulliparous women between menarche and <40 years on the risk of overall breast cancer and seven subtypes. This work builds on previous research to further the investigation into the influence of BMI during critical periods on breast cancer risk (*13, 14, 32*). Motivated by recent findings suggesting that a larger prepubertal body size, used as a proxy for BMI, may offer protection against breast cancer risk, while later life body size shows very little effect, we aimed to better understand the interval between puberty and later life. Specifically, we focused on the period between menarche and first full-term pregnancy, a crucial window of vulnerability for later life breast cancer development.

We observed variation in genetic effects on BMI across different life stages for nine of the 45 discovery variants identified in this study. Some of this variation may reflect statistical fluctuation introduced by selecting lead SNPs based on age-stratified significance thresholds. However, several variants showed clear changes in the direction of effect across the life stage groups. These directional shifts are unlikely to be due to random variation alone and suggest that the influence of certain genetic variants on BMI may differ depending on developmental stage. In addition, genome-wide cross-lifestage genetic correlations demonstrated variation, e.g., when comparing prepubertal body size and later life body size with BMI from menarche to <40 years.

In the univariable MR analyses, higher BMI in nulliparous women from menarche to <40 years was found to consistently reduce risk of overall breast cancer and most subtypes. Similar protective effects were observed when BMI was measured within narrower periods of this window (menarche to <20, 20 to <30, and 30 to <40 years). These protective effects largely remained after accounting for later life adult body size. In contrast, adjusting for prepubertal body size in multivariable MR led to greater attenuation, indicating that part of the protective effect of BMI in early reproductive life may be explained by body size before puberty. The attenuation was more pronounced for the narrower life-stage periods than for the full fertile-window measure, reflecting both biological and methodological influences. Biologically, part of the apparent effect across all reproductive-age windows overlaps with childhood adiposity, so adjustment for prepubertal body size reduces the estimates. Methodologically, the narrower age-specific GWASs have substantially smaller sample sizes than the childhood GWAS. In multivariable MR, this imbalance can magnify the degree of attenuation by limiting power to detect effects independent of childhood size. By contrast, the broader reproductive-age measure is based on a larger GWAS sample and therefore shows less attenuation, despite adjustment for the same childhood body size data. Importantly, no such attenuation was observed when adjusting for later-life body size, even though similar sample size imbalances exist. This indicates that differential power alone may not fully explain the observed

368 differences. Future methodological work is needed to examine how sample size disparities
369 across life-stage GWASs influence estimates in multivariable MR and to develop strategies for
370 accounting for this in lifecourse applications.
371
372 Our findings are in line with previous MR and conventional epidemiological studies reporting a
373 strong protective effect of early-life adiposity on breast cancer risk (*13-24*). Simulations
374 suggest that selection bias alone is unlikely to account for this association (*27*). Although bias
375 arose, it fell short of the effect sizes reported in earlier work. This study extends these earlier
376 analyses by exploring adiposity at additional life stages. The attenuation of associations with
377 post-menarche BMI after adjusting for prepubertal body size suggests that earlier adiposity
378 may, at least in part, confound estimates for later periods. Given that the protective effect of
379 early-life adiposity is unlikely to arise from selection bias alone, these results reinforce the
380 importance of accounting for early-life exposures when evaluating causal effects across the
381 lifecourse.
382
383 Evidence suggests that two distinct early-life pathways influence breast cancer risk: one linked
384 to greater body size and the other to earlier age at menarche (*13*). While a larger body size in
385 early life appears protective, it may also accelerate age at menarche, which is itself a risk factor
386 for breast cancer, suggesting that these pathways are not only independent but may interact
387 in complex ways. To isolate the direct effect of BMI independent of pubertal timing, we applied
388 MVMR controlling for age at menarche. However, the genetic architecture of age at menarche
389 and early-life adiposity overlaps substantially (*33*). A recent genome-wide structural equation
390 model integrating MoBa childhood BMI, recalled adiposity at age 10 in UK Biobank, and age at
391 menarche estimated that nearly half of the genetic variants associated with menarche act
392 through early-life adiposity (*33, 34*). This overlap has also been supported by longitudinal twin
393 studies (*35*). While this indicates strong shared genetic pathways, a proportion of menarche-
394 associated variants likely do act independently of adiposity. Nonetheless, BMI-related
395 pathways to earlier menarche may contribute more strongly to identified SNP signals than non-
396 BMI influences, complicating interpretation of MVMR estimates. Thus, although MVMR
397 provides a valuable sensitivity analysis, it may not fully disentangle the independent
398 contributions of adiposity and pubertal timing, particularly where shared pathways act
399 differently across breast cancer subtypes. Furthermore, increased prepubertal body size has
400 been shown to decrease breast density, while age at menarche has been linked to higher
401 breast density, which is another important risk factor for breast cancer (*32, 36*). This distinction
402 between pathways highlights the need to examine potential mediating factors, which may help
403 clarify the mechanisms at play. A deeper investigation into these separate but intersecting
404 pathways could reveal novel insights into breast cancer risk.
405
406 The relationship between body size and breast cancer risk is further complicated by
407 menopausal status. In conventional epidemiological settings, higher BMI has been linked to an
408 increased risk of breast cancer in postmenopausal women and a decreased risk of breast

409 cancer in premenopausal women (*37-40*). A plausible explanation includes the differing levels
410 of oestrogen exposure between women experiencing overweight and normal-weight (*41*).
411 Premenopausal women experiencing overweight tend to have longer anovulatory cycles,
412 which reduces their exposure to ovarian hormones, potentially lowering their breast cancer
413 risk. After menopause, fat tissue serves as another source of oestrogen production, which
414 increases breast cancer risk among overweight women (*42-45*). Whilst our study did not
415 specifically examine the relationship between overweight status and breast cancer pre- and
416 post- menopause, effect estimates were broadly consistent across subtypes, with only modest
417 differences in magnitude. The most evident departure from this pattern was seen in the HER2-
418 enriched subtype, which showed little evidence of protection in either univariable or
419 multivariable MR, potentially reflecting its distinct biology and the clinical observation that
420 overweight and obesity can worsen prognosis in early-stage HER2-positive breast cancer (*46*).
421 Lacking hormonal regulation, HER2-enriched tumours that depend on aberrant HER2 pathway
422 activation may be less affected by adiposity-related changes in oestrogen, SHBG, or IGF-1. In
423 contrast, Luminal B-like (HER2+) tumours appeared to retain evidence of a residual protective
424 effect across the full reproductive-life window (menarche to <40 years), even after adjustment
425 for prepubertal body size. This difference may reflect the continued influence of hormone-
426 dependent pathways in Luminal B-like (HER2+), which could mediate BMI-related protection
427 through endocrine or metabolic mechanisms despite HER2 expression. Previous MR studies of
428 childhood body size support such subtype-specific mechanisms; for example, mammographic
429 density, particularly dense area, appears to mediate much of the protective effect for ER-
430 positive but not ER-negative breast cancer (*32*), and hormonal mediators such as IGF-1 and
431 SHBG appear relevant mainly for ER-positive disease (*13*). These findings underscore the
432 importance of considering breast cancer subtypes when evaluating the long-term effects of
433 adiposity across the lifecourse.
434
435 This study is an important analysis with multiple strengths. It focuses on a previously
436 unexamined life stage – the period between menarche and under 40 years in nulliparous
437 women – to investigate the impact of increased BMI on breast cancer risk using causal
438 inference methods. By examining this life stage, we provide evidence on how adiposity before
439 and during early reproductive life may influence breast cancer development. This focus also
440 minimises potential confounding from the physiological changes associated with a first
441 pregnancy, allowing clearer interpretation of life-stage-specific effects. To strengthen the
442 analysis, we integrated data from five large European longitudinal cohort studies. This
443 approach allowed us to gain key insights into the consistency of BMI-related genetic effects
444 across different stages of life. In addition, these data are not only useful for this particular study
445 but also offer a valuable resource for future research into the effects of BMI in women at this
446 life stage on other health outcomes.
447
448 This study has several limitations that should be considered when interpreting the findings.
449 First, low conditional F-statistics were observed in the MVMR analysis, indicating potential for

weak instrument bias. As a result, our MVMR findings should be interpreted with some caution. However, the pattern of attenuation observed when adjusting for pre-pubertal body size was not replicated when adjusting for later life adult body size, despite both exposures being derived from GWAS with similar sample sizes and instrument strength. This asymmetry supports the interpretation that the differences in effect estimates are unlikely to be driven by weak instrument bias alone and likely reflect biologically distinct influences of body size at different developmental stages. In addition, while we combined data from five large European longitudinal cohorts, the sample size remains smaller (N=56,628) than that available for comparable measures of prepubertal and later life body size derived using in UK Biobank data (N=246,511). This reduced sample size may limit statistical power for detecting smaller effect sizes. Second, we used a prepubertal GWAS based on reported body size rather than measured BMI, as it offered a much larger sample size than any other GWAS of BMI at this life stage. However, this choice may distort MVMR analysis due to measurement error or differences in variance of effect sizes. Future work to precisely estimate childhood body size genetic effects are warranted. Third, there is the possibility of participant overlap between the HUNT and MoBa cohorts. The HUNT Study began in 1984-86, recruiting adults aged ≥20 in Nord-Trøndelag County across four cycles for over 30 years (*47*). Its Young-HUNT sub-studies recruited adolescents aged 13-19 in four waves between 1995 and 2019. MoBa, in contrast, recruited pregnant women nationally between 1999 and 2008 via routine prenatal care (*48*). Although up to 10% of MoBa participants resided in the Nord-Trøndelag catchment area, the differing recruitment criteria and time frames mean that any overlap with HUNT participants is expected to be minimal and unlikely to materially influence the analyses. Some participants in HUNT may have also participated in MoBa, which could introduce a degree of sample duplication. Fourth, the inclusion criteria for this study resulted in substantially smaller analytic samples compared to the total number of participants enrolled in each cohort. Although genotyping was not based on specific phenotypes, we acknowledge that, as in all large-scale genetic studies, selection bias due to differential data availability may still be present. Lastly, as our analysis was restricted to individuals of European ancestry, the generalisability of our findings to other populations is limited. Further research is needed to confirm these findings in more diverse populations.

Conclusion

This study offers important insights into the genetic influences on BMI across different life stages and its causal relationship with breast cancer risk, focusing on the period between menarche and under 40 years in nulliparous women as a key window of susceptibility. While higher BMI in this interval appeared strongly protective against breast cancer in univariable analyses, the effect substantially, though not entirely, attenutated after accounting for childhood body size, used as a proxy for BMI. This pattern suggests that the protection may arise from the combined influence of greater adiposity in both childhood and early adulthood.

These results have important implications for breast cancer prevention, underscoring earlier life stages as critical periods for potential interventions.

492 Materials and methods.
493
494 This study adheres to the Strengthening The Reporting of Observational Studies in
495 Epidemiology Using Mendelian Randomisation (STROBE-MR) guidelines (Table S9).
496
497 Data sources and study design
498
499 *Inclusion criteria and participating cohorts*
500
501 This study included five large, population-based prospective cohorts with available genomic
502 and phenotypic BMI data from nulliparous women between menarche and age <40 years: the
503 Avon Longitudinal Study of Parents and Children (ALSPAC), the Trøndelag Health Study (HUNT),
504 the Norwegian Mother, Father and Child Cohort Study (MoBa), Generation R, and Generation
505 Scotland. Participant selection is shown in Figure 1.
506
507 ALSPAC. ALSPAC is a birth cohort which enrolled 14,541 pregnant women living in Avon,
508 England with expected dates of delivery between April 1, 1991, and December 31, 1992 (the
509 estimated recruitment rate of those eligible was 80%) (*49-51*). Further enrolments after 1998
510 resulted in a baseline sample of 14,901 children alive at one year of age. Some study data were
511 collected and managed using Research Electronic Data Capture (REDCap) electronic data
512 capture tools hosted at the University of Bristol (*52*). Please note that the study website
513 contains details of all the data that is available through a fully searchable data dictionary and
514 variable search tool: http://www.bristol.ac.uk/alspac/researchers/our-data/. We used data
515 collected on women prior to pregnancy and their daughters in the 17 and 24-year follow up
516 groups that had information on genotype, menarche, BMI and age. We included 3,125 ALSPAC
517 mothers and 3,496 daughters from the offspring generation in the age-stratified analysis. In
518 the analysis focused on individuals between menarche and first birth (if pregnancy occurred
519 within this timeframe), we included 3,125 ALSPAC mothers and 1,922 daughters.
520
521 HUNT. HUNT is a cohort study of the adult population in Trøndelag County, Norway, and
522 comprises ~230,000 individuals aged ≥20 years (*47, 53*). Individuals were recruited in four
523 surveys from 1984–2019, of which the HUNT2 and HUNT3 surveys were included in the
524 present study. Invitee participation rates were 69% and 54%, respectively. Data on perinatal
525 outcomes are available via linkage to the Medical Birth Registry of Norway (MBRN) (*54*) for
526 individuals born from 1967 onwards. The full recruited sample of mothers was 64,098. A total
527 of 69,716 offspring were available in HUNT, with genotype and measured phenotype
528 information, of which 36,938 were female (*55, 56*). A total of 7,683 individuals were used in
529 this study.
530

MoBa. MoBa is a population-based pregnancy cohort study conducted by the Norwegian Institute of Public Health (*48*). Participants were recruited from all over Norway from 1999 to 2008, with 41% of all pregnant women invited consenting to participate. Blood samples were obtained from both parents during pregnancy and from mothers and children (umbilical cord) at birth (*57*). The first child was born in October 1999 and the last in July 2009. The cohort includes approximately 114,500 children, 95,200 mothers, and 75,200 fathers. Additionally, MoBa was linked to data from the Medical Birth Registry (MBRN), a national health registry containing information about all births in Norway from 1967 onwards (*54*). This analysis used a total of 31,471 MoBa first time mothers and 7,216 daughters from the offspring generation with information on genotype, menarche, BMI, age and parity.

Generation R. The Generation R Study is a population-based prospective cohort from fetal life onwards in Rotterdam, the Netherlands (*58*). Women with an expected delivery date between April 2002 and January 2006 living in Rotterdam were eligible to enrol the study, and written informed consent was obtained from all participants. A total 9,778 mothers, who gave birth to 9,749 live-born children, enrolled in the study. Genotype data were available for a total of 7,236 mothers, of which 3,450 were first-time mothers of singleton children and had information on pre-pregnancy BMI (*59*). Maternal age and pre-pregnancy weight were reported by the mother and height was measured at intake. A total of 2,396 women contributed to this GWAS.

Generation Scotland. Generation Scotland is a population-based cohort with ~20,000 participants from across Scotland, aged between 18 and 98 years. During 2006 to 2010, potential participants (aged 35–65 years) were identified and invited to join at random from collaborating general medical practices in Scotland. Participants were asked to identify ≥1 first-degree relatives aged ≥18 years who would also be able to participate. Subsequently, participants attended a staffed research clinic, completed a health questionnaire, and had physical and clinical characteristics measured according to a standardized protocol. Fasting blood and urine samples were collected, according to standard operating procedures. The full recruited sample of female participants was 14,152, of which 3,059 were included in this study and 2,815 contributed to the GWAS.

Given the focus of the research question, only female participants were included in the GWAS. Inclusion criteria required that participants had genotype data that passed quality control, had reached menarche, and had BMI measured while still nulliparous. For mothers in birth cohorts, this corresponded to pre-pregnancy BMI at the time of the index pregnancy, provided they had not given birth previously. Participants also needed to have complete covariate information. Analyses were further restricted to individuals aged under 40 to focus on early adulthood and the reproductive years. To minimise potential population stratification bias, we further limited the sample to participants of European genetic ancestry.

572
573 *Genotyping, quality control and imputation in each cohort*
574
575 Genotyping, quality control and imputation for each cohort are described in detail in
576 Supplementary Text and elsewhere (*56, 59-61*). Briefly, participants were genotyped using
577 genome-wide SNP arrays, and imputation was performed using standard reference panels
578 following cohort-specific quality control (QC) protocols. ALSPAC mothers and children were
579 genotyped using Illumina Human660K and HumanHap550 arrays, respectively, with
580 imputation via Haplotype Reference Consortium (HRC) v1.1. HUNT samples were genotyped
581 using three Illumina HumanCoreExome arrays, with imputation performed using Minimac3 and
582 a customized HRC v1.1 reference panel (*56, 60*). MoBa sampels were genotyped across 24
583 batches with varying selection criteria, centers, and arrays. The European Genome-Phenome
584 Archive HRC v1.1 (Study ID EGAS00001001710) was used for phasing and imputation (*48, 61*).
585 Generation R mothers were genotyped using Illumina GSA-MD 2.0 and 3.0 arrays, with
586 imputation against the 1000 Genomes Phase 3 v5 reference panel (*58, 59*). Generation
587 Scotland samples were genotyped using the Illumina HumanOmniExpressExome-8v1 chip, with
588 imputation via HRC.r1-1 on the Sanger Imputation Server.
589
590 *Statistical methods*
591
592 *Lifestage-stratified genome-wide association studies (GWAS) and meta-analysis*
593
594 We aimed to establish lifestage-specific genetic effect profiles for BMI. This was to (i) assess
595 the consistency of genetic variant effects on BMI across different life stages (including
596 prepubertal and later life adulthood, where body size was used as a proxy for BMI based on
597 previously derived genome-wide association studies (GWAS) from UK Biobank data (*14*)) and
598 (ii) applying these profiles in downstream lifecourse MR analyses. To achieve this, we
599 conducted GWAS on lifestage-stratified BMI values across life stage that has not been
600 previously investigated. Specifically, separate GWAS analyses were run on nulliparous women
601 between menarche and <40 years. These analyses were further stratified into three life stages:
602 <20 years, 20 to <30 years, and 30 to <40 years. We define these as life stages, as they are
603 anchored to each individual's age at menarche – a biological milestone that varies between
604 individuals – rather than being defined by absolute age alone. For BMI measurements from
605 mothers in birth cohorts, we extracted pre-pregnancy data from women who had not given
606 birth previously. For cohorts with repeat measures within a single life stage (e.g., menarche to
607 <40 years), we selected the measure with the largest sample size (e.g., ALSPAC offspring BMI
608 data from menarche to <20-year-olds). A complete-case approach was used, excluding
609 individuals with missing values from the analysis. Due to the skewed distribution of BMI in the
610 data, a natural log transformation was applied prior to running the GWAS analyses within each
611 cohort. Each cohort followed a shared GWAS framework using GCTA v1.93.2beta (*62*). While
612 general quality control (QC) guidelines and analysis scripts were provided via a GitHub

613 repository, individual studies conducted pre-imputation QC independently, applying
614 thresholds appropriate to their cohort data (Supplementary Text and elsewhere (*56, 59-61*)).
615 All analyses were restricted post hoc to common genetic variants with a minor allele frequency
616 (MAF) ≥ 0.01. Genome-wide association analyses were conducted using
617 GCTA's *fastGWA* linear mixed model (*63*). To adjust for related individuals (e.g. mothers and
618 daughters or other close relatives), a genetic relationship matrix (GRM) was constructed from
619 participants and converted into a sparse GRM using a relatedness threshold of 0.05. Age and
620 the top 20 genetic principal components were included as covariates, with the principal
621 components adjusting for population structure.
622
623 We meta-analysed summary statistics from the five cohorts for each lifestage-specific GWAS
624 separately, using a fixed effects model employed in METAL version 2020-05-05 (*64*). We
625 carried out further standard quality control QC procedures (*65*) including tests for bias due to
626 population structure (genomic control inflation factor [λ] and Linkage Disequilibrium Score
627 Regression [LDSC] (*66*)). We also estimated SNP heritability and assessed genetic correlations
628 between our meta-analysed GWAS and GWAS derived using UK Biobank data of prepubertal
629 body size and later life adult body size (*14*). Analyses were performed using the LDSC software
630 v1.0.0 (https://github.com/bulik/ldsc) employing default parameters. We used linkage
631 disequilibrium (LD) scores from European participants of the 1000 genomes project that can
632 be downloaded from the LDSC website. We generated Manhattan plots which contain
633 horizontal lines drawn at $-\log10(1\times10^{-5})$ for "suggestive associations" and $-\log10(5\times10^{-8})$ for
634 the 'genome-wide significant' threshold and QQ plots (Figure S2-S5) (*67*).
635
636 We used LD clumping with an r^2 threshold of 0.001 and a p-value threshold of 5×10^{-8} to select
637 a set of independent instruments for BMI at each life stage. This was performed using PLINK
638 (*68*) and genotype data from European individuals from phase 3 v5 enrolled in the 1000
639 genomes project as a reference panel (*69*).
640
641 We visualised the life stage-specific effect trajectories of these SNPs at each life stage
642 (menarche to <20 years, 20 to <30 years and 30 to <40 years), with point size inversely
643 proportional to the standard error of the effect estimate. We focused exclusively on SNPs
644 derived from the life stages analysed in this study and did not include those from other studies
645 due to differences in effect size scales. For example, body size measures for prepubertal and
646 later adulthood stages, derived from UK Biobank data, were based on body size categories
647 rather than BMI, making direct comparisons inconsistent (*14*).
648
649 *Publicly available genome-wide association study (GWAS) data*
650
651 We used publicly available breast cancer data from the Breast Cancer Association Consortium
652 (BCAC) from 2017 (N=228,951; ER+/ER- samples, extracted from OpenGWAS under IDs: ieu-a-
653 1127, ieu-a-1128) (*28*) and the latest release of BCAC from 2020 (N=247,173; overall sample

654 and five molecular subtypes: Luminal A-like, Luminal B-like (HER2-positive), Luminal B (HER2-
655 negative-like), HER2-enriched, and triple-negative breast cancer (*29*) (details in Table S10). The
656 2017 dataset included 69,501 ER+ cases and 21,468 ER- cases, with 105,974 shared controls.
657 The 2020 dataset included 63,767 Luminal A-like cases, 15,942 Luminal B-like (HER2-positive)
658 cases, 15,942 Luminal B (HER2-negative-like cases, 10,628 HER2-enriched cases, and 8,602
659 triple-negative breast cancer (TNBC) cases, all with 91,477 controls. Luminal A-like tumours are
660 characterized by ER+ and/or PR+, HER2- status, and low histologic grade (grade 1-2); Luminal
661 B-like (HER2+) tumours are characterized by ER+ and/or PR+, and HER2+ status; Luminal
662 B/HER2-negative-like tumours are characterized by ER+ and/or PR+, HER2- status, and high
663 histologic grade (grade 3); HER2-enriched-like tumours are defined as HER2+, ER–, and PR–;
664 and triple-negative tumours are defined as ER-, PR-, and HER2-. The cohort design and
665 genotyping protocol details are described elsewhere (bcac.ccge.medschl.cam.ac.uk/bcac-
666 groups/study-groups/, bcac.ccge.medschl.cam.ac.uk/bcacdata/). The study groups in the BCAC
667 consortium do not include ALSPAC, HUNT, MoBa, Generation R, Generation Scotland or UK
668 Biobank cohorts.
669
670 For comparative purposes, we utilised previously conducted GWASs of prepubertal and later
671 life adult body size, used as a proxy for BMI, previously undertaken in the UK Biobank study on
672 246,511 females. These GWAS represent the largest available sample size for body size in these
673 life stages. GWASs were adjusted for age and genotyping chip and genetic variants were
674 selected based on $P<5\times10^{-8}$ and $r^2<0.001$ (*14, 70, 71*). UK Biobank data were collected
675 between 2006 and 2010 on individuals aged between 40 and 69 years old at baseline, including
676 data from clinical examinations, assays of biological samples, detailed information on self-
677 reported health characteristics, and genome-wide genotyping, using a prospective cohort
678 study design (*71*). The prepubertal body size measure utilised recall questionnaire data,
679 involving responses from adult participants who were asked whether, compared to the
680 average, they were 'thinner', 'about average' or 'plumper', when they were aged 10 years old.
681 The adult body size variable was derived using clinically measured body mass index (BMI) data
682 (mean age 56.5 years). It was then separated into a 3-tier variable using the same categories
683 as the childhood body size measure for comparability; "thinner" (21.1 kg/m^2-25 kg/m^2), "about
684 average" (25 kg/m^2-31.7 kg/m^2) and "plumper" (31.7 kg/m^2-59.9 kg/m^2) (*14*). These scores
685 have been independently validated in three distinct cohorts, providing verification that these
686 genetic instruments can reliably separate childhood and adult BMI (*14, 72, 73*).
687
688 To disentangle whether our results were influenced by age at menarche, we used publicly
689 available data (Age when periods started (menarche)) from the UK Biobank cohort where
690 female individuals were asked 'How old were you when your periods started?'. This GWAS was
691 conducted in 2014 (N=182,416, extracted from OpenGWAS under ID: ieu-a-1095)). To
692 investigate the potential for collider bias resulting from restricting our analyses to nulliparous
693 women we used publicly available parity data (Number of live births) from the UK Biobank
694 cohort from 2018 (N=250,782, extracted from OpenGWAS under ID: ukb-b-1209). This

695 phenotype includes individuals with zero live births, thereby capturing variation from
696 nulliparity onwards and serving as a useful proxy for parity-related bias.
697
698 *Lifecourse Mendelian randomization (MR) analysis*
699
700 Our primary two-sample MR analyses used the inverse variance weighted (IVW) estimator,
701 implemented in the TwoSampleMR R package (*74*). When genetic variants are used as
702 instrumental variables in MR, the assumptions of instrumental variables must be met, i.e., the
703 genetic variants used must (i) be strongly associated with the exposure of interest
704 ("relevance"), (ii) not share common causes with the outcome ("independence"), and (iii) not
705 affect the outcome other than through the exposure ("exclusion-restriction") (*75*). We
706 conducted sensitivity analyses, which relax the assumptions made about horizontal pleiotropy,
707 including MR Egger regression (*76*), and the weighted median-based estimator (*77*). We also
708 applied Steiger filtering (*78*) to test the direction of causality between BMI between menarche
709 and first birth and breast cancer risk, by assessing whether the genetic instruments explained
710 more variance in the exposure than in the outcome. In addition we conducted analyses using
711 the MR-RAPS method which is robust to weak instruments and systematic pleiotropy (*79*). To
712 allow the inclusion of a larger set of instruments, we applied a liberal SNP selection threshold
713 of $P<1\times10^{-5}$. We ran IVW multivariable MR (MVMR), an extension of MR that employs multiple
714 genetic variants associated with multiple measured risk factors, to calculate the direct and
715 indirect effects of BMI between menarche and first birth on breast cancer outcomes. For each
716 MVMR model, we included all SNPs associated with either of the two traits, encompassing both
717 trait-specific (G1 and G2) and shared (G12) variants, as illustrated in Figures 2B and 2C. Genetic
718 variants associated with each exposure were first pruned for LD to ensure instrument
719 independence. The resulting SNP lists were then combined across exposures, and any duplicate
720 variants present in both instruments were retained only once in the initial combined set. This
721 full combined list was then re-pruned for LD to further ensure independence across all
722 instruments used in the MVMR analysis. This final pruned set was then used to extract
723 harmonised summary statistics for all traits. As the MVMR framework accounts for correlations
724 between exposures and accommodates pleiotropy, this approach supports estimation of
725 exposure-specific effects and facilitates clearer interpretation of the independent
726 contributions of each exposure.
727
728
729 This analysis accounted for prepubertal and later life adult body size separately (Figures 5A, B
730 and C). These two additional time points were not included together in a single model due to
731 the risk of weak instrument bias. Instrument strength was evaluated using the two-sample
732 conditional *F*-statistic described elsewhere (*80*).
733
734 To improve interpretability and biological relevance, all MR effect estimates have been scaled
735 to represent the effect per one standard deviation (SD) increase in log-tranformed BMI at each

736 of the life stages. In addition, these estimates reflect the effect of genetic liability to BMI over
737 particular life stages and should not be interpreted as equivalent to the effect size or duration
738 of a time-limited intervention (*81*). This distinction is important when considering the clinical
739 or public health implications of our findings.
740



741
742
743 *Figure 5. Directed acyclic graphs indicating three scenarios to explain the causal effect between BMI in*
744 *nulliparous women between menarche and <40 years and breast cancer in later life. A. BMI in*
745 *nulliparous women between menarche and <40 years has a total causal effect on breast cancer. B. BMI*
746 *in nulliparous women between menarche and <40 years has a total causal effect on breast cancer,*
747 *independent of prepubertal body size. C. BMI in nulliparous women between menarche and <40 years*
748 *has a total causal effect on breast cancer, independent of later life adult body size.*
749

Sensitivity analyses

To minimise pregnancy-related confounding, we restricted the BMI exposure GWAS to nulliparous women, enabling a clearer assessment of BMI's direct influence across life stages. In contrast, the breast cancer outcome GWAS included both nulliparous and parous women. This discrepancy in selection mechanisms introduces potential selection bias in the genetic effect estimates for BMI but not for breast cancer. Specifically, conditioning on parity in the BMI GWAS may induce bias in the estimated SNP effects on BMI ($\hat{\beta}_{Gx}$), whereas breast cancer estimates ($\hat{\beta}_{Gy}$), remain unaffected as parity was not conditioned on in the outcome GWAS (Eq. 1).

In this two-sample MR setting, the MR estimate is given by:

$$\hat{\beta}_{MR} = \frac{\hat{\beta}_{Gy}}{\hat{\beta}_{Gx}} \quad \text{(Eq. 1)}$$

Where:

$$E(\hat{\beta}_{Gx}) = \beta_{Gx} + \text{bias}$$

$$E(\hat{\beta}_{Gy}) = \beta_{Gy}$$

Since $\hat{\beta}_{Gy}$ is not subject to the same selection mechanism and there is no reason to assume that the selection-induced bias in β_{Gx} is correlated with $\hat{\beta}_{Gy}$, a major spurious association in the MR analysis is unlikely. However, selection bias in the BMI GWAS could distort the MR estimate, with the direction and magnitude depending on whether and how BMI influences parity within the restricted sample. In an extreme scenario it could induce false positive associations with BMI that arise due to collider bias though this is unlikely at current sample sizes.

To empirically assess this, we performed univariable MR analyses estimating the effect of parity on BMI in nulliparous women across different life stages (menarche to <40 years, <20 years, 20 to <30 years, and 30 to <40 years). While parity itself cannot causally influence BMI in nulliparous women, genetic variants associated with parity may exhibit pleiotropic effects on BMI through shared metabolic and reproductive pathways. If these parity-associated variants also influence BMI within our restricted sample, it would suggest selection bias related to reproductive behaviour, implying that conditioning on parity in the BMI GWAS may have introduced collider bias. We additionally conducted the reverse analysis, estimating the effect of early-life BMI-associated variants on parity, to assess the potential for bias in the opposite direction.

789
790 In addition, a later onset of menarche has been linked to a reduced risk of breast cancer (*82,*
791 *83*). Childhood body size has been shown to accelerate the timing of menarche, whilst an
792 earlier menarche increases the likelihood of increased body size in adulthood (*84, 85*). With
793 these traits sharing a complex and interconnected relationship, we conduct sensitivity analyses
794 estimating the effect of BMI in the lifestages analysed in nulliparous women on overall breast
795 cancer accounting for age at menarche in MVMR analyses. Age at menarche is treated as a
796 confounder, given its influence both BMI and breast cancer risk through hormonal and
797 metabolic pathways. Including it in the MVMR model ensures that observed BMI effects are
798 not simply a reflection of differences in pubertal timing. However, we note that MVMR
799 adjustment for age at menarche is complicated by the substantial genetic overlap between
800 prepubertal BMI and menarche timing (*33*).
801
802 We conducted statistical analyses in R version 4.3.3 (*86*).

803 **References.**
804

805 1. M. Arnold et al., Current and future burden of breast cancer: Global statistics for 2020
806 and 2040. The Breast 66, 15-23 (2022).
807 2. . (Updated June 2024.).
808 3. Y. Liu et al., Physical activity from menarche to first pregnancy and risk of breast cancer.
809 International Journal of Cancer 139, 1223-1230 (2016).
810 4. G. A. Colditz, K. Bohlke, C. S. Berkey, Breast cancer risk accumulation starts early:
811 prevention must also. Breast Cancer Res Treat 145, 567-579 (2014).
812 5. M. Ciwinska et al., Mechanisms that clear mutations drive field cancerization in
813 mammary tissue. Nature 633, 198-206 (2024).
814 6. Y. Liu et al., Alcohol intake between menarche and first pregnancy: a prospective study
815 of breast cancer risk. J Natl Cancer Inst 105, 1571-1578 (2013).
816 7. Alcohol consumption and ethyl carbamate. IARC Monogr Eval Carcinog Risks Hum 96,
817 3-1383 (2010).
818 8. G. Davey Smith, S. Ebrahim, 'Mendelian randomization': can genetic epidemiology
819 contribute to understanding environmental determinants of disease? Int J Epidemiol
820 32, 1-22 (2003).
821 9. E. Sanderson et al., Mendelian randomization. Nat Rev Methods Primers 2, (2022).
822 10. G. M. Power et al., Methodological approaches, challenges, and opportunities in the
823 application of Mendelian randomisation to lifecourse epidemiology: A systematic
824 literature review. Eur J Epidemiol 39, 501-520 (2024).
825 11. E. Sanderson, G. Davey Smith, F. Windmeijer, J. Bowden, An examination of
826 multivariable Mendelian randomization in the single-sample and two-sample summary
827 data settings. Int J Epidemiol 48, 713-727 (2019).
828 12. E. Sanderson, T. G. Richardson, T. T. Morris, K. Tilling, G. Davey Smith, Estimation of
829 causal effects of a time-varying exposure at multiple time points through multivariable
830 mendelian randomization. PLoS Genet 18, e1010290 (2022).
831 13. M. Vabistsevits et al., Deciphering how early life adiposity influences breast cancer risk
832 using Mendelian randomization. Commun Biol 5, 337 (2022).
833 14. T. G. Richardson, E. Sanderson, B. Elsworth, K. Tilling, G. Davey Smith, Use of genetic
834 variation to separate the effects of early and later life adiposity on disease risk:
835 mendelian randomisation study. BMJ 369, m1203 (2020).
836 15. Y. Hao et al., Reassessing the causal role of obesity in breast cancer susceptibility: a
837 comprehensive multivariable Mendelian randomization investigating the distribution
838 and timing of exposure. Int J Epidemiol 52, 58-70 (2023).
839 16. G. M. Power et al., A structural mean modelling Mendelian randomization approach to
840 investigate the lifecourse effect of adiposity: applied and methodological
841 considerations. American Journal of Epidemiology, (2025).
842 17. B. W. Jensen et al., Childhood body mass index trajectories, adult-onset type 2 diabetes,
843 and obesity-related cancers. J Natl Cancer Inst 115, 43-51 (2023).
844 18. G. Fagherazzi, G. Guillas, M.-C. Boutron-Ruault, F. Clavel-Chapelon, S. Mesrine, Body
845 shape throughout life and the risk for breast cancer at adulthood in the French E3N
846 cohort. European Journal of Cancer Prevention 22, 29-37 (2013).
847 19. M. Song et al., Trajectory of body shape across the lifespan and cancer risk. Int J Cancer
848 138, 2383-2395 (2016).

20. T. O. Yang et al., Body size in early life and the risk of postmenopausal breast cancer. BMC cancer 22, 232 (2022).
21. A. Llewellyn, M. Simmonds, C. G. Owen, N. Woolacott, Childhood obesity as a predictor of morbidity in adulthood: a systematic review and meta-analysis. Obesity reviews 17, 56-67 (2016).
22. D. Byun et al., Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies. Br J Cancer 126, 664-672 (2022).
23. Z. J. Andersen et al., Birth weight, childhood body mass index, and height in relation to mammographic density and breast cancer: a register-based cohort study. Breast Cancer Research 16, R4 (2014).
24. T. G. Richardson, H. Urquijo, M. V. Holmes, G. Davey Smith, Leveraging family history data to disentangle time-varying effects on disease risk using lifecourse mendelian randomization. European Journal of Epidemiology 38, 765-769 (2023).
25. C. M. Schooling, K. Fei, J. V. Zhao, Selection bias as an explanation for the observed protective association of childhood adiposity with breast cancer. J Clin Epidemiol 164, 104-111 (2023).
26. A. Gkatzionis, S. R. Seaman, R. A. Hughes, K. Tilling, Relationship between collider bias and interactions on the log-additive scale. Stat Methods Med Res, 9622802241306860 (2025).
27. G. M. Power, E. Sanderson, G. Davey Smith, G. Hemani, Selection bias is unlikely to fully explain the protective effect of childhood adiposity on breast cancer risk. Zenodo., (2025).
28. K. Michailidou et al., Association analysis identifies 65 new breast cancer risk loci. Nature 551, 92-94 (2017).
29. H. Zhang et al., Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet 52, 572-581 (2020).
30. J. Zheng et al., LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. Bioinformatics 33, 272-279 (2017).
31. M. R. Munafò, K. Tilling, A. E. Taylor, D. M. Evans, G. Davey Smith, Collider scope: when selection bias can substantially influence observed associations. Int J Epidemiol 47, 226-235 (2018).
32. M. Vabistsevits et al., Mammographic density mediates the protective effect of early-life body size on breast cancer risk. Nat Commun 15, 4021 (2024).
33. K. A. Kentistou et al., The role of common and rare genetic variation on adiposity across childhood. medRxiv, 2025.2005.2013.25327505 (2025).
34. K. A. Kentistou et al., Understanding the genetic complexity of puberty timing across the allele frequency spectrum. Nat Genet 56, 1397-1411 (2024).
35. K. Silventoinen, A. Jelenkovic, T. Palviainen, L. Dunkel, J. Kaprio, The Association Between Puberty Timing and Body Mass Index in a Longitudinal Setting: The Contribution of Genetic Factors. Behavior Genetics 52, 186-194 (2022).
36. R. Lloyd et al., The Prospective Association between Early Life Growth and Breast Density in Young Adult Women. Cancers. 2024 (10.3390/cancers16132418).
37. T. X. M. Tran et al., Adiposity, Body Composition Measures, and Breast Cancer Risk in Korean Premenopausal Women. JAMA Network Open 7, e245423-e245423 (2024).

38. P. A. van den Brandt et al., Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152, 514-527 (2000).
39. P. A. van den Brandt et al., Body size and weight change over adulthood and risk of breast cancer by menopausal and hormone receptor status: a pooled analysis of 20 prospective cohort studies. Eur J Epidemiol 36, 37-55 (2021).
40. T. Dehesh et al., The relation between obesity and breast cancer risk in women by considering menstruation status and geographical variations: a systematic review and meta-analysis. BMC Women's Health 23, 392 (2023).
41. C. M. Friedenreich, Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 10, 15-32 (2001).
42. M. L. Neuhouser et al., Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA Oncol 1, 611-621 (2015).
43. I. Glassman et al., The Role of Obesity in Breast Cancer Pathogenesis. Cells 12, (2023).
44. R. S. Cecchini et al., Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res (Phila) 5, 583-592 (2012).
45. P. Zhao, N. Xia, H. Zhang, T. Deng, The Metabolic Syndrome Is a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis. Obes Facts 13, 384-396 (2020).
46. F. Ligorio et al., Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications. Ther Adv Med Oncol 14, 17588359221079123 (2022).
47. B. O. Åsvold et al., Cohort Profile Update: The HUNT Study, Norway. International Journal of Epidemiology 52, e80-e91 (2022).
48. P. Magnus et al., Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). International Journal of Epidemiology 45, 382-388 (2016).
49. A. Fraser et al., Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol 42, 97-110 (2013).
50. A. Boyd et al., Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol 42, 111-127 (2013).
51. K. Northstone et al., The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample of index children in 2019. Wellcome Open Res 4, 51 (2019).
52. P. A. Harris et al., Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42, 377-381 (2009).
53. S. Krokstad et al., Cohort Profile: the HUNT Study, Norway. Int J Epidemiol 42, 968-977 (2013).
54. L. M. Irgens, The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand 79, 435-439 (2000).
55. G.-H. Moen et al., Mendelian randomization study of maternal influences on birthweight and future cardiometabolic risk in the HUNT cohort. Nature Communications 11, 5404 (2020).
56. B. M. Brumpton et al., The HUNT study: A population-based cohort for genetic research. Cell Genom 2, 100193 (2022).
57. L. Paltiel et al., The biobank of the Norwegian Mother and Child Cohort Study – present status. Norsk Epidemiologi 24, (2014).

58. M. N. Kooijman et al., The Generation R Study: design and cohort update 2017. Eur J Epidemiol 31, 1243-1264 (2016).
59. S. Ghatan et al., Genetic Nurture: Estimating the direct genetic effects of pediatric anthropometric traits. medRxiv, 2024.2012.2010.24318796 (2024).
60. M. Næss et al., Data Resource Profile: The HUNT Biobank. Int J Epidemiol 53, (2024).
61. E. C. Corfield et al., The Norwegian Mother, Father, and Child cohort study (MoBa) genotyping data resource: MoBaPsychGen pipeline v.1. bioRxiv, 2022.2006.2023.496289 (2024).
62. J. Yang, S. H. Lee, M. E. Goddard, P. M. Visscher, GCTA: A Tool for Genome-wide Complex Trait Analysis. The American Journal of Human Genetics 88, 76-82 (2011).
63. L. Jiang et al., A resource-efficient tool for mixed model association analysis of large-scale data. Nature Genetics 51, 1749-1755 (2019).
64. C. J. Willer, Y. Li, G. R. Abecasis, METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190-2191 (2010).
65. A. Ani, P. J. van der Most, H. Snieder, A. Vaez, I. M. Nolte, GWASinspector: comprehensive quality control of genome-wide association study results. Bioinformatics 37, 129-130 (2021).
66. B. K. Bulik-Sullivan et al., LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nature genetics 47, 291 (2015).
67. S. S. Paria, S. R. Rahman, K. Adhikari, fastman: A fast algorithm for visualizing GWAS results using Manhattan and Q-Q plots. bioRxiv, 2022.2004.2019.488738 (2022).
68. C. C. Chang et al., Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).
69. G. R. Abecasis et al., An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
70. C. Sudlow et al., UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12, e1001779 (2015).
71. C. Bycroft et al., The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203-209 (2018).
72. M. Brandkvist et al., Separating the genetics of childhood and adult obesity: a validation study of genetic scores for body mass index in adolescence and adulthood in the HUNT Study. Hum Mol Genet 29, 3966-3973 (2021).
73. T. G. Richardson et al., Evaluating the direct effects of childhood adiposity on adult systemic metabolism: a multivariable Mendelian randomization analysis. Int J Epidemiol, (2021).
74. G. Hemani et al., The MR-Base platform supports systematic causal inference across the human phenome. Elife 7, e34408 (2018).
75. R. C. Richmond, G. Davey Smith, Mendelian Randomization: Concepts and Scope. Cold Spring Harb Perspect Med 12, (2022).
76. J. Bowden, G. Davey Smith, S. Burgess, Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International journal of epidemiology 44, 512-525 (2015).
77. J. Bowden, G. Davey Smith, P. C. Haycock, S. Burgess, Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genetic epidemiology 40, 304-314 (2016).

78. G. Hemani, K. Tilling, G. Davey Smith, Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet 13, e1007081 (2017).
79. Q. Zhao, J. Wang, G. Hemani, J. Bowden, D. S. Small, Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. (2020).
80. E. Sanderson, W. Spiller, J. Bowden, Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. Stat Med 40, 5434-5452 (2021).
81. B. Woolf, S. Burgess, The role of estimation in Mendelian randomization: should Mendelian randomization investigations provide estimates? AJE Advances: Research in Epidemiology 1, (2025).
82. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. The Lancet Oncology 13, 1141-1151 (2012).
83. G. V. Dall, K. L. Britt, Estrogen Effects on the Mammary Gland in Early and Late Life and Breast Cancer Risk. Front Oncol 7, 110 (2017).
84. F. Juul, V. W. Chang, P. Brar, N. Parekh, Birth weight, early life weight gain and age at menarche: a systematic review of longitudinal studies. Obes Rev 18, 1272-1288 (2017).
85. C. Prince, L. D. Howe, G. C. Sharp, A. Fraser, R. C. Richmond, Establishing the relationships between adiposity and reproductive factors: a multivariable Mendelian randomization analysis. BMC Med 21, 350 (2023).
86. R Core Team. (R Foundation for Statistical Computing, Vienna, Austria, 2020).
87. R. Wootton, & Havdahl, A. . (2025).

1012 Acknowledgements.
1013 We are extremely grateful to all the families who took part in this study, the midwives for their
1014 help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer
1015 and laboratory technicians, clerical workers, research scientists, volunteers, managers,
1016 receptionists, and nurses. The authors would also like to thank the research participants of the
1017 HUNT study which is a collaboration between HUNT Research Centre (Faculty of Medicine and
1018 Health Sciences, NTNU Norwegian University of Science and Technology), Trøndelag County
1019 Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public
1020 Health. The HUNT genotype quality control and imputation has been conducted by the K.G.
1021 Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of
1022 Medicine and Health Sciences, NTNU. In addition, we are grateful to all the families who took
1023 part, the general practitioners and the Scottish School of Primary Care for their help in
1024 recruiting them, and the whole Generation Scotland team, which includes interviewers,
1025 computer and laboratory technicians, clerical workers, research scientists, volunteers,
1026 managers, receptionists, healthcare assistants and nurses. The Norwegian Mother, Father and
1027 Child (MoBa) Cohort Study is supported by the Norwegian Ministry of Health and Care Services
1028 and the Ministry of Education and Research. We are grateful to all the participating families in
1029 Norway who take part in this on-going cohort study. We thank the Norwegian Institute of
1030 Public Health (NIPH) for generating genomic data as part of the HARVEST collaboration,
1031 supported by the Research Council of Norway (#229624). We also thank the NORMENT Centre
1032 for providing genotype data, funded by the Research Council of Norway (#223273), South East
1033 Norway Health Authorities and Stiftelsen Kristian Gerhard Jebsen, and conducted by deCODE
1034 Genetics. We further thank the Center for Diabetes Research, the University of Bergen for
1035 providing genotype data and performing quality control and imputation of the data funded by
1036 the ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn
1037 Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the University of
1038 Bergen, and the Western Norway Health Authorities. The MoBa analyses of BMI were carried
1039 out as part of the Lifecourse GWAS Consortium through the PsychGen multimorbidity project
1040 (REK 2016/1702), and in contribution to the project "Combining Mendelian Randomisation and
1041 Depression Trajectories to Better Inform Intervention Timing" (*87*). The MoBa analyses were
1042 performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo,
1043 operated and developed by the TSD service group at the University of Oslo, IT Department
1044 (USIT) (tsd-drift@usit.uio.no). The analyses were performed using resources provided by
1045 Sigma2 - the National Infrastructure for High-Performance Computing and Data Storage in
1046 Norway. The Generation R Study is conducted by Erasmus MC in close collaboration with the
1047 School of Law and Faculty of Social Sciences of the Erasmus University Rotterdam, the
1048 Municipal Health Service Rotterdam area, Rotterdam, the Rotterdam Homecare Foundation,
1049 Rotterdam, and the Stichting Trombosedienst & Artsenlaboratorium Rijnmond (STAR-MDC),
1050 Rotterdam. We gratefully acknowledge the contribution of children and parents, general
1051 practitioners, hospitals, midwives, and pharmacies in Rotterdam. The generation and
1052 management of GWAS genotype data for the Generation R Study was done at the Human

Genomics Facility, HuGe-F, housed within the Laboratory for Population Genomics of the Department of Internal Medicine at Erasmus MC. Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, The Netherlands. We thank Pascal Arp, Gaby van Dijk, Marijn Verkerk, Samuel Gathan, Dr. Linda Broer and Jard de Vries for their help in creating, managing and QCing the GWAS database.

Funding.

The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. GMP, AH, GL, ES, RR, GH, and GDS were supported by the Integrative Epidemiology Unit which receives funding from the UK Medical Research Council and the University of Bristol (MC_UU_00032/1). GDS conducts research at the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. The genotyping in HUNT was supported by the National Institutes of Health (NIH); University of Michigan; The Research Council of Norway (RCN); The Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St. Olavs hospital and the Faculty of Medicine and Health Sciences, NTNU. LB, BOA, and BMB work in a research unit financially supported by the Liaison Committee for education, research and innovation in Central Norway and the Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU. This study used data from Medical Birth Registry of Norway (MBRN). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression Longitudinally" (STRADL) Reference 104036/Z/14/Z. CH was supported by an MRC University Unit core grant MC_UU_00007/10 (QTL in Health and Disease program). BLL acknowledges support from the University of Bristol (Vice-Chancellor's Research Fellowship), Academy of Medical Sciences/Wellcome Trust/the Government Department of Business, Energy and Industrial Strategy/British Heart Foundation/Diabetes UK Springboard Award (SBF003/1170), Elizabeth Blackwell Institute for Health Research (University of Bristol), and Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z) and Wellcome Trust Career Development Award (227849/Z/23/Z). AH was supported by the Research Council of Norway (#336085) and the South-Eastern Norway Regional Health Authority (#2020022; #2922083; #2019097; #2018059; #2021045). The general design of the Generation R Study is made possible by financial support from Erasmus MC, University Medical Center Rotterdam, Erasmus University Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Netherlands Organization for Scientific Research (NWO), the Ministry of Health, Welfare and Sport, and the Ministry of

Youth and Families. The parental genotyping in Generation R was supported by the ERC under the European Union's Horizon 2020 research and innovation programme (iRISK; grant agreement No 863981). This project received funding from the European Union's Horizon Europe Research and Innovation Programme under grant agreement nº 101137146 (STAGE project). UK participants in Horizon Europe Project STAGE are supported by UKRI grant numbers 10112787 (Beta Technology), 10099041 (University of Bristol) and 10109957 (Imperial College London).

Research Ethics and Informed Consent.

Informed consent for cohort participation was obtained from all participants and ethical approval was obtained from the Regional Committee for Medical and Health Research Ethics, Central Norway (REK Central application number 2018/2488) (HUNT), the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees (ALSPAC), and the Medical Ethical Committee of Erasmus MC, University Medical Center Rotterdam, approved the study (MEC 198.782/2001/31) (Generation R), and The Regional Committees for Medical and Health Research Ethics (REK application number 2016/1702) (MoBa). Written consent was obtained from all participants in Generation Scotland. All components of Generation Scotland received ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). Generation Scotland has also been granted Research Tissue Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 20-ES-0021).

Author Contributions.

Conceptualization: GMP, GDS; Methodology: GMP, GH; Formal analysis: GMP, LB, AMH, CMG, DM AR; Data curation: GMP, LB, AMH, AMG, AR, ECC; Writing – original draft: GMP; Writing – review & editing: GMP, LB, AMH, CMG, AR, GL, BLL, ES, RR, ECC, DM, CH, IFM, FR, BOÅ, GH, JFF, BB, AH, GDS; Visualisation: GMP, Supervision: GDS, GH, AH, BB, JFF, CH; Project administration: GMP; Funding acquisition: GDS, GH, AH

Competing interests.

Daniel McCartney is an employee of Optima Partners Ltd. All authors declare no other competing interests.

Data and Materials Availability.

Data access for the Avon Longitudinal Study of Parents and Children (ALSPAC) operates via a managed open access system. Approved proposals are reviewed by the ALSPAC Executive Committee. Full details are provided in the ALSPAC Data Management Plan (www.bristol.ac.uk/alspac/researchers/data-access/documents/alspac-data-management-plan.pdf). Data from the Norwegian Mother, Father and Child (MoBa) Cohort Study is managed by the Norwegian Institute of Public Health. Access is provided upon approval from the Regional Committees for Medical and Health Research Ethics (REC), compliance with GDPR, and data owner approval. Participant consent does not allow individual-level data

storage in repositories or journals. Researchers seeking access for replication must apply via www.helsedata.no. To request access to data from the Trøndelag Health Study (HUNT), researchers affiliated with Norwegian research institutes can apply for the use of HUNT data and biological samples, subject to approval by the Regional Committee for Medical and Health Research Ethics. Researchers from other countries may also apply if collaborating with a Norwegian Principal Investigator. All applications are reviewed by the HUNT Data Access Committee, and successful applicants are required to enter into data access and/or material transfer agreements. Detailed information on the application process, ethical requirements, and available datasets can be found on the HUNT website (www.ntnu.edu/hunt/data). Data from Generation Scotland are available on application to an independent access committee. More information can be found on the Generation Scotland website (www.generationscotland.org). Data from the Generation R Study are available upon reasonable request to the director of the Generation R Study (generationr@erasmusmc.nl), subject to local, national and European rules and regulations.

All genetic instruments derived in this study are in the supplementary tables. Genome-wide association study summary statistics will be made available on a public repository upon publication.

Code provided to collaborators for conducting the GWAS of BMI between menarche and first birth is available at: https://github.com/gracemarionpower/Collaboration_MA_BMI_M2FB.

None of the material has been published or is under consideration for publication elsewhere.